Naoko Takebe to Proto-Oncogene Proteins c-kit
This is a "connection" page, showing publications Naoko Takebe has written about Proto-Oncogene Proteins c-kit.
Connection Strength
0.369
-
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clin Cancer Res. 2017 Jun 15; 23(12):2972-2980.
Score: 0.141
-
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016 Feb; 27(2):318-23.
Score: 0.131
-
KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Jun 08; 305(22):2327-34.
Score: 0.096